CONSORT Diagram
The data cutoff for the interim analysis was September 16, 2022.The median number of treatment cycles was 4 (range, 1-26) in arm B and 2 (range, 1-10) in arm A (eTable 2 in The primary end point was met. Treatment with panitumumab plus trifluridine-tipiracil resulted in longer PFS, with 52% reduction in the risk of progression (HR, 0.48; 95% CI, 0.28-0.82; 